GRAIL Faces Securities Fraud Lawsuit Following NHS-Galleri Trial Failure

The litigation centers on the period between May 13, 2025, and February 19, 2026, during which GRAIL executives reportedly touted the trial’s three-year follow-up period as sufficient to demonstrate a reduction in late-stage cancer diagnoses. Plaintiffs contend that leadership selectively highlighted favorable data while withholding internal indicators that the study’s timeline was fundamentally inadequate to reach its primary endpoint.

Market confidence evaporated on February 19, 2026, when the company disclosed the trial's failure to meet its primary goal and admitted that the follow-up period should have been longer. The resulting sell-off saw GRAL shares plummet by 50.55% in a single session, erasing more than $2.2 billion in market capitalization. Hagens Berman Sobol Shapiro LLP, the firm representing the class, is now investigating exactly when management realized the three-year duration was insufficient for the trial’s stated objectives.

Reed Kathrein, the partner leading the investigation, stated that the firm is scrutinizing the timeline of internal awareness regarding these clinical limitations. Investors who purchased shares during the class period are encouraged to contact legal counsel before the court-mandated deadline to participate in the proceedings.